Axicabtagene ciloleucel

Therapeutic indications

Axicabtagene ciloleucel is indicated for:

Primary mediastinal large B-cell lymphoma (PMBCL)

Population group: both men and women, only adults (18 - 65 years old)

Αxicabtagene ciloleucel is indicated for the treatment of adult patients with primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Population group: both men and women, only adults (18 - 65 years old)

Αxicabtagene ciloleucel is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines